EPIDIOLEX DIN 02543079
Status: Marketed
Holder: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Molecule: CANNABIDIOL
Available to quote
Health Canada record
| Active ingredient(s) | CANNABIDIOL 100 MG |
|---|---|
| Dosage form | Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N03AX24 CANNABIDIOL |
| Original market date | 28-Mar-2024 |
| Current status date | 10-Dec-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jazz Pharmaceuticals Canada Inc. — licence 3-002453, currently licensed, last inspection rating C (2024-12-02).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 33226 | 2024-05-16 | New Drug Submission (NDS) | Administrative: Manufacturer Name Change |
| 32096 | 2023-11-15 | New Drug Submission (NDS) |
International API supply for CANNABIDIOL
3 valid EDQM Certificates of Suitability from 3 holders. 24 active FDA Drug Master Files.
Request a quote for EPIDIOLEX